RBM7 Inhibitors

The chemical class described as RBM7 inhibitors comprises compounds that influence the functions associated with RBM7 through various cellular pathways. These inhibitors target mechanisms such as transcription regulation, stress response signaling, RNA splicing, and RNA degradation. By modulating these pathways and processes, they can indirectly affect the roles played by RBM7 in the NEXT complex, DNA damage response, and stress response. Compounds like Flavopiridol and DRB inhibit CDK9, a key component of the P-TEFb complex, which is involved in transcription regulation and DDR. This inhibition can indirectly impact the transcription of DDR genes, a process in which RBM7 participates. Ruxolitinib and SB 203580, which inhibit JAK1/2 and p38 MAPK respectively, can modulate stress response pathways, thereby influencing RBM7's function during stress response.

Spliceostatin A and Pladienolide B target the splicing machinery, which is crucial for pre-mRNA processing. Since RBM7 is associated with newly synthesized RNAs including pre-mRNAs, affecting splicing can indirectly influence RBM7's role in RNA processing and turnover. U0126, an MEK inhibitor, also plays a role in modulating stress response pathways. Exportin inhibitors like KPT-330 and Leptomycin B impact nuclear RNA export, a process that can influence RNA processing and degradation, potentially affecting RBM7's function. CX-5461 and BMH-21, by inhibiting RNA Polymerase I, affect ribosomal RNA synthesis, which is a stress-related process where RBM7 might play a role. Lastly, ISRIB, by inhibiting the Integrated Stress Response (ISR), offers a means to explore how modulating cellular stress responses can impact RBM7-related functions. In summary, this group of RBM7 inhibitors, through their action on various pathways and processes, provides insights into strategies for modulating the activities related to RBM7 in RNA processing, stress response, and DNA damage response.